Ocular Therapeutix shifts Axpaxli's approval strategy, raising valuation risks and regulatory uncertainty. Click here to read ...

Capricor Therapeutics faces high regulatory risks for its DMD therapy. Get expert analysis on trial data and FDA challenges.

The National Organization for Rare Disorders (NORD®) today urged Congress to reauthorize the Rare Pediatric Disease Priority Review Voucher (RPD PRV) program by year-end, warning that continued delay ...

Onctura initiates phase I/II trial of roginolisib in patients with myelofibrosis who are no longer responding to JAK inhibition: Geneva, Switzerland Friday, December 5, 2025, 15: ...

SINGAPORE,First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinib among Asian patients.

When you open Premiere Elements, you first see the Home screen, a separate window from which you can launch any of the three ...

USPTO issues notice of allowance to Mezzion Pharmaceuticals for its udenafil exclusivity in Fontan patients: Fort Lee, New Jersey Saturday, December 6, 2025, 16:00 Hrs [IST] Mezzi ...

December on extending enhanced Affordable Care Act subsidies, but Republicans still can’t decide whether they want to put ...

Novartis announced new MONALEESA pooled analysis results showing that 25% of HR+/HER2- metastatic breast cancer patients treated first-line with Kisqali plus endocrine therapy remained ...

There are several new options in theaters this weekend, including Quentin Tarantino's Kill Bill: The Whole Bloody Affair, the ...

If you're currently an Android beta tester and you want to update to Android 16 QPR2 without a data wipe, now is the time.

Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor ...